entertainment -WSS

entertainment

author：focus 2025-09-27 16:49:13 - browse：7953

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed. Joe Raedle/Getty Images

Walmart seems poised to increase its health care footprint by buying value-based senior care company ChenMed, per reports from Bloomberg.

Experts largely hailed the rumored sale as a good buy, citing the management of chronic conditions in the Medicare Advantage population through primary care, ChenMed’s specialty, as an area with huge innovation and cost savings over the last 10 years.

“If you’re going to purchase primary care in the senior space, there’s no one better than ChenMed. The only other one that might be better or equivalent would be Oak Street, but they were just purchased,” said Jon Kaplan, a senior partner at BCG. “In the world of great primary care practices to buy, in my top two are Oak Street and ChenMed, and one of them’s available, one’s not.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

WSS

FDA poised to publish guidelines for clinical trial diversity

FDA panel gives mixed vote on blood pressure devices

How a symptom of dementia informs our understanding of creativity

H5N1 bird flu outbreak: Second human case reported, in Michigan

Questions and answers about ramping up H5N1 bird flu vaccine

Apellis safety probe of eye disease drug centers on injection needle

hotspot

entertainment

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Eyeing GLP

Psychedelics group wrestles with new pharma identity

Apellis safety probe of eye disease drug centers on injection needle

Moonlake's readout produced a cash windfall. Risks remain

CDC advisory panel says seniors 'may' get RSV vaccine

Wildfire smoke exposes gaps in outdoor worker protections

AstraZeneca bets AAV gene therapy will still deliver the goods

Medicare details structure of new drug price negotiation program

Australia’s approach to dialysis celebrates life

focus

Apellis safety probe of eye disease drug centers on injection needle

At flashy new research hub, AstraZeneca lays out ambitious growth goals

UnitedHealth argues against case alleging wrongful AI care denials

Apellis safety probe of eye disease drug centers on injection needle

Cue Health, Covid

Feds fine Medicare Advantage plans for overcharging members

focus

focus

focus

leisure time